Vascular Endothelial Growth Factor-Trap Overcomes Defects in Dendritic Cell Differentiation but Does Not Improve Antigen-Specific Immune Responses
暂无分享,去创建一个
J. Sosman | Ji‐Hyun Lee | J. Dupont | A. Jackson | D. Gabrilovich | Craig A. Lockhart | Noweeda N Mirza | Ingo Fricke | J. Lee
[1] Ingo Fricke,et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. , 2006, Cancer research.
[2] K. Kikuchi,et al. Vascular endothelial growth factor and dendritic cells in human squamous cell carcinoma of the oral cavity. , 2006, Anticancer research.
[3] D. Gabrilovich,et al. Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer , 2006, Cancer Immunology, Immunotherapy.
[4] Paolo Serafini,et al. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.
[5] L. Kaiser,et al. Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.
[6] G. Watanabe,et al. Prognostic value of CD83-positive mature dendritic cells and their relation to vascular endothelial growth factor in advanced human gastric cancer. , 2005, Oncology reports.
[7] M. D. Della Porta,et al. Dendritic Cells and Vascular Endothelial Growth Factor in Colorectal Cancer: Correlations with Clinicobiological Findings , 2005, Oncology.
[8] S. Signoretti,et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. , 2005, Cancer research.
[9] D. Gabrilovich. Mechanisms and functional significance of tumour-induced dendritic-cell defects , 2004, Nature Reviews Immunology.
[10] H. Fujii,et al. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines , 2004, Cancer Immunology, Immunotherapy.
[11] M. Hicks,et al. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] B. Han,et al. [Vascular endothelial growth factor inhibits dendritic cells from patients with non-small cell lung carcinoma]. , 2003, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[13] Bin Yu,et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. , 2003, Cancer research.
[14] C. Myers,et al. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment , 2003, Breast Cancer Research.
[15] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[16] K. Kikuchi,et al. Vascular Endothelial Growth Factor and Dendritic Cells in Squamous Cell Carcinoma of the Oral Cavity , 2002 .
[17] M. Mandalà,et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. , 2001, Journal of biological regulators and homeostatic agents.
[18] Nicholas R. English,et al. Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.
[19] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[20] D. Carbone,et al. Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[22] D. Carbone,et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] D. Carbone,et al. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. , 1999, Journal of immunology.
[24] Ishida,et al. Dendritic cells transduced with wild‐type p53 gene elicit potent anti‐tumour immune responses , 1999, Clinical and experimental immunology.
[25] D. Carbone,et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.
[26] S. Tsujitani,et al. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. , 1998, British Journal of Cancer.
[27] S. Rosenberg,et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. , 1998, Journal of immunology.
[28] D. Carbone,et al. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. , 1998, Journal of immunology.
[29] D. Carbone,et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. , 1998, Journal of immunology.
[30] D. Carbone,et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] L. Ellis,et al. Angiogenesis and metastasis. , 1996, European journal of cancer.
[32] D. Carbone,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.
[33] J. Berzofsky,et al. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. , 1996, Cellular immunology.
[34] M. Toi,et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer , 1996, Cancer.
[35] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[36] D. Carbone,et al. Erratum: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (Nature Medicine 2, 1096-1103 (1996)) , 1996 .